Skip to NavigationSkip to content


FDA shutters MSD’s Keytruda combination trials in myeloma

Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have to be stopped, comes the complete halt called to three trials involving Keytruda.

MSD struck in second global cyber attack

Following the recent and heavily-publicised ransomware attack which hit the NHS in the UK and almost 100 other countries, the world has found itself in the midst of another. The vehicle for the attack, a virus dubbed Petya, has been reported in countries including Russia, the UK, and the US. Among the firms affected is US pharmaceutical company MSD, or Merck as it is known in its own country.

MSD allays Irish fears with €280m expansion investment

IMAGE: Anna & Michal

There were fears in Ireland that President Trump’s strong words to bring manufacturing back to the US would hurt the Irish economy, as US headquartered companies paused operations to determine whether they would have to scale back investment. MSD’s pause, in particular, has now come to an end with a committed of €280 million and the creation of 330 new roles across two sites in Ireland.

MSD receives first FDA approval based on specific genetic feature

In a historic first, MSD (known as Merck in North America) has received approval for its immunotherapy treatment Keytruda in patients with a specific genetic feature, otherwise known as a biomarker. This means that patients who have a biomarker known as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) will be able to receive the treatment.

MSD under CMA investigation over unfair Remicade pricing

MSD is facing legal trouble after the Competition and Marketing Authority (CMA) alleged that the pharmaceutical firm had engaged in anti-competition practices by implementing an unfair discount scheme for one of its top drugs, Remicade (infliximab).

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region is set to grow by more than 100% to be worth $6.2 billion by 2023, up from $3 billion in 2016. The advent of key therapies including BMS’ Yervoy (ipilimumab) and necitumumab, also known as Eli Lilly’s Portrazza is given as primary drivers of this growth.

MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. The particular indication is within patients who are refractory to treatment or who have relapsed after three or more previous attempts at treatment.

Immunotherapy: The three major treatments that are changing cancer prognoses

Published on 13/03/17 at 11:56am

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, 2016 was the year where it really came to the fore. We examine the leading immunotherapies in the market and their development as we move further into 2017.

From the moment of the first indication for a first-line treatment, immunotherapy became the go-to treatment for a select group of patients, and the results it demonstrated were more than encouraging – even if they were only available to specific candidates for treatment.

NICE knocks back MSD's Keytruda for lung cancer indication

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for the treatment of untreated PD-L1-positive metastatic lung cancer.

NICE’s decision was spurred by the “immaturity of the data” provided by MSD, which made it impossible to accurately determine Keytruda’s overall survival benefits compared to current standard of care.

MSD’s investigational cytomegalovirus treatment shows significant promise in Phase 3 trial

MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing the treatment hit its primary endpoint of an improvement in clinically significant cytomegalovirus (CMV) infection following a bone marrow transplant.

A non-nucleoside CMV inhibitor, letermovir is currently in development as a preventative treatment of CVM infection in adult CMV-seropositive patients who have received an allogeneic hematopoietic stem cell transplant (HSCT).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches